Esbriet

Chemical Namepirfenidone
Dosage FormCapsule/Tablet (oral; 267 mg/267 mg, 801 mg)
Drug ClassMiscellaneous
SystemRespiratory
CompanyGenentech Inc.
Approval Year2014

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Esbriet (pirfenidone) Prescribing Information2014Genentech USA, Inc., South San Francisco, CA